Recent regulatory developments in India have highlighted the importance of keeping drug manufacturing licence information accurate and up to date. The reported government initiative aims to address situations where cancelled or suspended manufacturing licences may not be updated quickly in regulatory and procurement systems. This could allow companies with invalid licences to continue participating in drug supply and procurement activities.

For pharmaceutical manufacturers, this is not only a licensing issue. It highlights an important point:

regulatory compliance must be maintained, monitored, and demonstrated continuously. It should not be addressed only when an inspection or regulatory action takes place.

A manufacturing licence is only one part of a larger compliance system. GMP practices, documentation, quality management, validation, facilities, utilities, employee training, data integrity, CAPA, and internal audits all play an important role in maintaining regulatory readiness.

1. Keep Manufacturing Licence Status Under Regular Review

Pharmaceutical companies should have a clear system to regularly check the status and validity of their manufacturing licences and other regulatory approvals.

Changes in manufacturing activities, products, premises, equipment, or regulatory requirements should trigger a review to confirm whether the existing licences and approvals are still applicable.

This responsibility should not be limited to one department. Regulatory, Quality, Production, Engineering, and other relevant teams should have clearly defined responsibilities for identifying and communicating changes that could affect the company's regulatory status.

A documented review process can help prevent situations where operational changes are made without updating the required licences or regulatory documents.

2. Do Not Consider a Valid Licence as the End of Compliance

Having a valid manufacturing licence does not automatically mean that a facility is ready for a regulatory inspection.

Compliance also depends on the systems and practices followed inside the facility. These include:

• GMP-compliant manufacturing practices
• Effective quality management systems
• Controlled and updated documentation
• Qualified equipment and utilities
• Validated processes and systems
• Proper environmental controls
• Strong data integrity controls
• Effective deviation and CAPA management
• Change control
• Employee training
• Regular internal self-inspections

A company may have a valid licence but still receive regulatory observations if its actual practices do not match approved procedures or applicable GMP requirements.

3. Make Sure Documentation Matches Current Operations

One of the most important compliance areas for pharmaceutical manufacturers is ensuring that documents accurately reflect what is happening on the shop floor.

SOPs, batch records, specifications, validation documents, equipment records, facility drawings, and other controlled documents should be reviewed whenever processes, equipment, facilities, or systems are changed.

A common compliance problem occurs when a facility changes over time but the related documentation is not updated.

For example, a change to a manufacturing area may affect HVAC systems, room classification, pressure differences, environmental monitoring, cleaning procedures, equipment qualification, or validation requirements.

4. Strengthen Change Control

Changes to facilities, equipment, processes, utilities, computerized systems, suppliers, or documentation should be reviewed through a formal change control process.

Change control is not simply about getting approval before making a change. It should help the company understand:

• Why the change is required?
• Which systems may be affected?
• What risks the change may create?
• Whether qualification or validation is required?
• Whether SOPs or employee training need to be updated?
• Whether regulatory notification or approval is required?
• Whether the change has achieved its intended result?

Weak change control can create differences between the approved condition of a facility and its actual operating condition.

5. Regularly Review Facility and Utility Compliance

Facility and utility systems are important parts of GMP compliance.

Pharmaceutical manufacturers should regularly review critical systems such as HVAC, cleanrooms, purified water, compressed air, gases, temperature and humidity controls, and other critical utilities.

The review should check whether:

• Qualification is still current
• Requalification is required after major changes
• Monitoring records are complete
• Calibration is up to date
• Environmental conditions remain within approved limits
• Preventive maintenance is being carried out
• Deviations are properly investigated

For HVAC and cleanroom systems, any changes in production areas or operating conditions should be evaluated to determine whether additional qualification or validation is required.

6. Strengthen Internal Audits and Self-Inspection

A strong self-inspection programme can help identify weaknesses before they become regulatory findings.

Internal audits should not only check whether documents are available. They should also verify whether employees are actually following the required procedures.

For example, an internal audit can check whether:

• Operators are following the current SOP
• Deviations are being properly investigated
• CAPAs address the actual root causes
• Equipment remains qualified
• Employees have suitable training for their assigned activities
• Data is complete and traceable
• Change controls are being implemented correctly

If internal audits repeatedly find no significant gaps, companies should also review whether the audit programme is sufficiently detailed, challenging, and independent.

7. Give Proper Attention to Data Integrity

Regulatory expectations now cover both paper-based documentation and electronic systems and digital records.

Pharmaceutical companies should ensure that data is:

• Attributable
• Legible
• Contemporaneous
• Original
• Accurate
• Complete
• Consistent
• Enduring
• Available

This includes reviewing electronic records, audit trails, laboratory systems, manufacturing systems, spreadsheets, access controls, backup procedures, and data review practices.

Data integrity should be treated as an operational responsibility. It should not be considered only the responsibility of the IT or Quality department.

8. Make CAPA Effectiveness a Priority

Closing a CAPA does not always mean that the original problem has been completely resolved.

An effective CAPA programme should confirm whether corrective and preventive actions have addressed the root cause and helped prevent the problem from happening again.

Companies should therefore include effectiveness checks as part of their CAPA process.

If the same deviation, complaint, or audit observation continues to occur, the company should review whether the original root-cause analysis and corrective action were strong enough.

9. Prepare Before the Next Regulatory Inspection

Inspection readiness should not start only after receiving an inspection announcement.

A pharmaceutical facility should maintain continuous inspection readiness by regularly reviewing its compliance status against applicable GMP requirements and regulatory expectations.

A structured gap assessment can help identify areas that need improvement and allow the company to prioritize corrective actions based on risk.

The review can include:

• Quality systems
• Manufacturing operations
• Documentation
• Facilities and utilities
• HVAC and cleanrooms
• Validation and qualification
• Data integrity
• Employee training
• CAPA
• Change control
• Regulatory documentation

The objective is simple: identify and correct compliance gaps before they become regulatory observations.

10. Build a Culture of Continuous Compliance

Effective compliance should not be the responsibility of the Quality department alone.

Regulatory compliance requires involvement from Production, Engineering, Quality Assurance, Quality Control, Validation, Regulatory Affairs, IT, Supply Chain, and senior management.

Every department should understand how its activities can affect the company's GMP and regulatory status.

A strong compliance culture develops when employees understand not only what procedure they need to follow, but also why the procedure is important and what risk it helps control.

What Does This Mean for Pharmaceutical Manufacturers?

The recent focus on drug manufacturing licence verification highlights the importance of maintaining strong regulatory controls throughout the pharmaceutical manufacturing lifecycle.

Companies should not wait for a licence suspension, regulatory observation, audit finding, or procurement issue before reviewing their compliance systems.

Instead, manufacturers should regularly ask:

• Is our current operating condition consistent with our approved and documented condition?
• Are our facilities, utilities, equipment, processes, and computerized systems properly qualified and controlled?
• Can we demonstrate our compliance through reliable documentation and accurate data?
• If a regulatory inspector visited our facility tomorrow, could we demonstrate effective control of our operations?

These questions form the foundation of genuine inspection readiness.

How Micron HVAC Can Support Compliance Readiness

At Micron HVAC, we support pharmaceutical manufacturers in strengthening GMP compliance, facility performance, validation, and regulatory readiness.

Our support includes:

• GMP and regulatory consultancy
• Compliance gap assessments
• Audit and inspection readiness
• HVAC and cleanroom qualification
• Facility and utility compliance
• Qualification and validation
• CAPA and remediation support
• Computerized system validation
• Greenfield project consultancy
• Brownfield project consultancy

Our approach focuses on identifying practical compliance gaps, understanding their potential impact, and developing suitable actions to strengthen the overall compliance framework.

Conclusion

Drug manufacturing licence compliance is only one part of a much larger regulatory responsibility.

As regulatory systems become more connected and authorities place greater importance on transparency, traceability, and accountability, pharmaceutical manufacturers need to keep their regulatory information accurate and ensure that their actual operations continue to meet GMP requirements.

Compliance readiness should not be something a company focuses on only before an inspection. It should be part of the way a pharmaceutical facility operates every day.

Organizations that regularly review their systems, identify compliance gaps, implement effective corrective actions, and maintain proper control over their facilities and processes will be better prepared to meet changing regulatory expectations.

Stay compliant. Stay inspection-ready. Stay prepared.